HOME >> BIOLOGY >> NEWS
Boat paint to blame for Norfolk Broads' desolation

One of the main culprits behind an environmental catastrophe that desolated one of Britain's most important wildlife habitats has finally been identified in a study led by researchers from UCL (University College London) and Acroloxus Wetlands Consultancy Ltd, Canada.

In the current issue of the journal Environmental Science & Technology, they reveal that introduction of the compound tributyltin (TBT) as a biocide in boat paint in the 1960s resulted in a dramatic and sudden loss of aquatic vegetation from most of the 50 or so Norfolk Broads lakes.

At the time, scientists pointed the finger at contamination from sewage works and fertiliser run-off from farmland, despite suggestions from the local community that the burgeoning leisure boating industry might be to blame.

Though the use of TBT was banned in freshwater systems in the UK in 1987, the researchers say 40 years on from TBT's introduction the fragile ecosystem remains shattered despite expensive attempts to restore it.

Dr Carl Sayer, of the UCL Environmental Change Research Centre, who co-led the study, says: "For too long TBT has been neglected as a driver of environmental destruction in freshwater wetlands and even though it is no longer in use in UK inland waterways, TBT contamination and its negative effects are still being reported all over the world.

"Real concerns have been raised about TBT derived from industrial and ship breaking activities in several major river systems including the Ganges, Brahmaputra and Yangtze all of which are connected to shallow lakes. In the case of the Yangtze, the linked shallow lakes are some of the largest in the world and, like the Broads, have experienced problems with plant loss on a large scale."

TBT was originally designed for use on the hulls of large ocean-going ships to reduce the build-up of barnacles. Since the 1970s it has been linked to a host of negative effects in the marine environment includ
'"/>

Contact: Judith H Moore
judith.moore@ucl.ac.uk
44-020-767-97678
University College London
18-Sep-2006


Page: 1 2

Related biology news :

1. Tumor painting revolutionizes fight against cancer
2. Engineers develop process to recycle unused paint by blending it into common plastics
3. Ancient war paint in fight against breast cancer
4. Study supports urgent need for worldwide ban on lead-based paint
5. Shampoo detergent added to paint makes surfaces self-sterilizing
6. In anoxia, why cant humans be more like western painted turtles?
7. Chemical used in marine paint may damage hearing in whales
8. Metabolic syndrome -- dont blame the belly fat
9. Bone and cartilage growth to blame for heart valve disease
10. Global warming - the blame is not with the plants
11. How do you feel? Genetics are partly to blame

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Boat paint blame for Norfolk Broads desolation

(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
Cached News: